Healthcare
Live Price
Offline$88.41
-0.10% today
1Y Change
-31.39%
Window
Jun 20, 2025 → Jun 9, 2026
Coverage: 243 bars · Jun 20, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Abbott Laboratories (ABT) is a Healthcare stock with a market cap of $152.55B and listed on NYSE. The stock last traded around $88.41 and down 31.4% across the available one-year price window (Jun 20, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of +5.7%, EPS growth of -51.2%, a dividend yield of 2.8%. What stands out right now is revenue +5.7%, EPS -51.2%, free cash flow +16.4% with operating margin 18.2% and ROIC 6.6%. The dividend matters to the case here, with a current yield around 2.8%. Valuation is more restrained than many high-expectation growth names at P/E 24.4 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines ABT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ABT
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ABT Max Drawdown
-40.21%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ABT and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$43.1B
-1.3% YoY
FY Net Income
$7.1B
+2.0% YoY
Free Cash Flow
$8.6B
+10.8% YoY
Revenue Growth
+5.7%
EPS Growth
-51.2%
Gross Margin
56.4%
Net Margin
13.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44.3B | 42.0B | 40.1B | 43.7B | 43.1B |
| Gross Profit | 24.6B | 21.3B | 20.0B | 22.3B | 23.2B |
| Operating Income | 8.0B | 6.8B | 6.4B | 8.4B | 9.2B |
| EBITDA | 11.6B | 10.8B | 10.6B | 11.9B | 12.2B |
| Net Income | 6.5B | 13.4B | 5.7B | 6.9B | 7.1B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8.5B | 7.6B | 6.9B | 9.9B | 9.8B |
| Total Assets | 86.7B | 81.4B | 73.2B | 74.4B | 75.2B |
| Total Liabilities | 33.9B | 33.5B | 34.4B | 37.5B | 39.2B |
| Shareholder Equity | 52.1B | 47.7B | 38.6B | 36.7B | 35.8B |
| Total Debt | 15.1B | 15.3B | 15.9B | 17.9B | 19.3B |
| Net Debt | 6.5B | 7.7B | 9.0B | 8.1B | 9.5B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
10.5B
+9.9% YoY
Capital Expenditures
1.9B
-6.1% YoY
Free Cash Flow
8.6B
+10.8% YoY
Key ratios
Gross Margin
56.4%
Operating Margin
18.2%
Net Margin
13.9%
ROE
12.2%
Debt / Equity
0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.